Aptose Biosciences Q2 2024 GAAP EPS $(0.43) Beats $(0.86) Estimate
Portfolio Pulse from Benzinga Newsdesk
Aptose Biosciences (NASDAQ:APTO) reported a Q2 2024 GAAP EPS of $(0.43), significantly beating the analyst consensus estimate of $(0.86) by 50%.
August 08, 2024 | 9:51 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Aptose Biosciences reported a Q2 2024 GAAP EPS of $(0.43), beating the analyst consensus estimate of $(0.86) by 50%.
The significant beat on earnings per share (EPS) is likely to positively impact the stock price in the short term as it indicates better-than-expected financial performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100